We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hematology Analyzer Evaluated for Reliability and Efficiency

By LabMedica International staff writers
Posted on 10 Dec 2012
A high throughput hematology analyzer is found to be reliable, efficient, as well as highly user-friendly and ergonomically designed. More...


A recently introduced series of hematology analyzers are able to carry out complete blood count (CBC), eight-part differential, reticulocyte and erythroblast analysis, as well as body fluids measurements (CBF).

Hematologists at St-Joseph St-Luc Hospital (Lyon, France) evaluated the Pentra DX Nexus analyzers, which offer 50 parameters and a high throughput of 120 samples per hour. The study used the XE-2100 (Sysmex; Kobe, Japan) as a reference system to compare the functions and ergonomics of the workcell. This consisted of a Pentra DX Nexus analyzer, SPS evolution slide maker/stainer and ABX Pentra ML data management system (HORIBA Medical; Northampton, UK).

The results of the evaluations show the instrument’s performance to be very good and the system offers significant improvements over previous generations of the Pentra analyzers for both traceability and ergonomics. The stability and precision functional evaluation of the results demonstrated that the technical abilities of the analyzer fulfilled stringent medical requirements and the manufacturer’s specifications.

A significant improvement in the new Pentra DX Nexus model is the color touch screen that uses easily identifiable icons to denote different functions of the analyzer. The virtual keyboard was found by the study participants to be more useful than a physical keyboard for entering data. Transferring data and hardware connections have also been made easier by multiple USB ports. In addition, a new laser source dissipates less heat and reduces the power requirements and noise generated by the instrument. The study found that the reduced size of the analyzer was also a positive attribute for laboratories, where space is of a premium.

Cleve Wright, General Manager of HORIBA Medical said, “With its new color touch screen and smart access to various functionalities, the Pentra Nexus is an exciting addition to our broad range of Pentra hematology analyzers. All are designed to meet our many differing customer requirements, both in the laboratory and at the point-of-care.”

Related Links:

St-Joseph St-Luc Hospital
Sysmex
HORIBA Medical



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Steam Sterilizer
Hi Vac II Line
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.